• Profile
Close

A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: The Prevention of Osteopenia with Minodronate And Denosumab (PROMADE) study

Osteoporosis International Feb 03, 2020

Yoshida, T, et al. - A randomized, open-label, controlled trial was designed to investigate whether monthly oral minodronate or semiannual subcutaneous injection of denosumab improves bone mineral density (BMD) in Asian men with prostate cancer (PCa) receiving ADT. A total of 147 individuals were recruited. Individuals were assigned randomly (1:1:1) to minodronate, denosumab, or no agent control groups. At 12 months, denosumab improved BMD at the femoral neck and total hip, whereas minodronate only increased BMD at the total hip compared with controls. In comparison with the control group, the percentage change in bone turnover markers at 12 months was significantly lower in the minodronate and denosumab groups. In Asian individuals with PCa, minodronate or denosumab can be applied for preventing bone loss related to ADT.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay